Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een fase 2-onderzoek naar Ianalumab (VAY736) bij patiënten met primaire immuuntrombocytopenie (ITP) die eerder werden behandeld met ten minste twee therapielijnen

19 oktober 2026 bijgewerkt door: Novartis Pharmaceuticals

Een fase 2-onderzoek om de werkzaamheid en veiligheid van Ianalumab (VAY736) te evalueren bij patiënten met primaire immuuntrombocytopenie (ITP) die eerder zijn behandeld met ten minste een corticosteroïde en een trombopoëtinereceptoragonist (TPO-RA)

The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patients with primary ITP previously treated with at least one corticosteroid and one TPO-RA.

Studie Overzicht

Toestand

Actief, niet wervend

Interventie / Behandeling

Gedetailleerde beschrijving

This is a phase 2, open-label, single-arm study to evaluate the efficacy, safety and tolerability of ianalumab in participants with primary ITP (platelet count <30 G/L at screening) previously treated with at least a corticosteroid and a TPO-RA.

The study consists of the screening period, the primary endpoint assessment period, the follow-up period. The screening period will last for up to 14 days prior to the first dose of ianalumab. All eligible participants will be treated with the same dose of ianalumab and will complete the primary endpoint assessment period. After completion of the primary endpoint assessment period, all participants will continue in safety monitoring and those with a platelet count ≥30 G/L in absence of a new line of ITP therapy and rescue therapy will also continue in efficacy monitoring. The trial includes an option to offer a second course of ianalumab treatment to participants who achieved confirmed response during the initial course of ianalumab and later lost response to explore the benefit of the second course of treatment. The study will end once all participants have completed 24 months of safety follow-up since their last dose of ianalumab (including the optional second course of ianalumab treatment),or discontinued the study earlier.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

41

Fase

  • Fase 2

Uitgebreide toegang

Verkrijgbaar buiten de klinische proef. Zie uitgebreid toegangsrecord.

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • CABA, Argentinië, C1181ACH
        • Novartis Investigative Site
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australië, 2605
        • Novartis Investigative Site
    • Victoria
      • Melbourne, Victoria, Australië, 3004
        • Novartis Investigative Site
      • Beijing, China, 100730
        • Novartis Investigative Site
      • Jinan, China, 250012
        • Novartis Investigative Site
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Novartis Investigative Site
      • Giessen, Duitsland, 35392
        • Novartis Investigative Site
    • Saxony
      • Dresden, Saxony, Duitsland, 01307
        • Novartis Investigative Site
    • Thuringia
      • Jena, Thuringia, Duitsland, 07740
        • Novartis Investigative Site
      • Toulouse, Frankrijk, 31059
        • Novartis Investigative Site
    • TO
      • Torino, TO, Italië, 10126
        • Novartis Investigative Site
      • Johor Bahru, Maleisië, 80100
        • Novartis Investigative Site
      • Katowice, Polen, 40-519
        • Novartis Investigative Site
    • Catalonia
      • Barcelona, Catalonia, Spanje, 08003
        • Novartis Investigative Site
      • Izmir, Turkije (Türkiye), 35100
        • Novartis Investigative Site
      • Kocaeli, Turkije (Türkiye), 41380
        • Novartis Investigative Site
    • Efeler
      • Aydin, Efeler, Turkije (Türkiye), 09100
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, Turkije (Türkiye), 34098
        • Novartis Investigative Site
    • Merkez
      • Edirne, Merkez, Turkije (Türkiye), 22030
        • Novartis Investigative Site
      • Glasgow, Verenigd Koninkrijk, G31 2ER
        • Novartis Investigative Site
      • London, Verenigd Koninkrijk, W12 0HS
        • Novartis Investigative Site
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Verenigde Staten, 02215
        • Beth Israel Deaconess Med Center
      • Seoul, Zuid -Korea, 06591
        • Novartis Investigative Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 100 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Signed informed consent obtained prior to participation in the study.

  • Male or female participants aged 18 years and older on the day of signing informed consent.

  • Confirmed diagnosis of primary ITP.

    • Prior treatment with at least a corticosteroid (±IVIG) and a TPO-RA:
    • Prior additional therapies are allowed; the corticosteroid or the TPO-RA do not need to be the last treatment.
    • Prior response to IVIG/anti-D or a corticosteroid (platelet count ≥50 G/L) that was not maintained.
  • At last ITP treatment, loss of response, insufficient response, no response or intolerance.

  • Platelet count <30 G/L and assessed as needing treatment (per physician's discretion) at screening. If concomitant ITP medication is clinically indicated, the platelet assessment showing a value <30 G/L must be performed after at least 14 days on a stable dose of a corticosteroid or/and a TPO-RA (less than 10% variation from current dose) and continue stable thereafter.

Key exclusion criteria:

  • Diagnosis of secondary thrombocytopenia.

  • Platelet or whole blood transfusion, plasmapheresis, or use of any other rescue medications within 14 days before first ianalumab infusion.

  • Participants with the following conditions at screening:

    • Neutrophils <1000/mm3.
    • Immunoglobulin G (IgG) <5 g/L
  • Treatment with a B-cell depleting therapy (e.g., rituximab) or anti-B-cell Activating Factor of the TNF Family (BAFF) (e.g., belimumab) within 12 weeks prior to the first administration of ianalumab.

  • Immunosuppressant drugs other than corticosteroids within 5 times the elimination half-life of the drug or 14 days before first ianalumab infusion, whichever is longer.

  • Prior splenectomy.

Other protocol-defined inclusion/exclusion criteria may apply.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Single-arm

All eligible participants will receive ianalumab at the same dose.

Intravenous infusion, prepared from concentrate solution

Andere namen:
  • VAY736

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Confirmed response
Tijdsspanne: Between Week 1 Day 1 and Week 25 Day 1

Confirmed response is defined as a platelet count of equal or above 50 G/L at two (or more) consecutive assessments at least 7 days apart, in the absence of:

  • Rescue treatment for ≥4 weeks prior to the assessment of the platelet count, and
  • New immune thrombocytopenia (ITP) treatment before reaching a confirmed response.
Between Week 1 Day 1 and Week 25 Day 1

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Time to confirmed response
Tijdsspanne: From Week 1 Day 1 to Week 25 Day 1

Time from the first administration of ianalumab to the first assessment in the first sequence of two (or more) platelet assessments meeting the criteria of a confirmed response as defined by the primary endpoint.

From Week 1 Day 1 to Week 25 Day 1
Duration of confirmed response
Tijdsspanne: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Time from the first assessment in the first sequence of two (or more) platelet assessments meeting the criteria of a confirmed response to loss of response; with loss of response defined as the first of the following events:

  • platelet count <30 G/L,
  • start of any rescue or new ITP treatment,
  • death (whatever the cause).
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Complete Response rate at each timepoint
Tijdsspanne: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Percentage of participants with a platelet count of at least 100 G/L in the absence of rescue treatment/new ITP treatment.

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Response rate at each timepoint
Tijdsspanne: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Percentage of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment.

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Stable response at 6 months
Tijdsspanne: At 6 months

Percentage of participants with at least 75% of platelet counts collected at month 6 (between study days 121 and 183) equal to or above 50 G/L in the absence of rescue treatment/new ITP treatment.

At 6 months
Stable response at 1 year
Tijdsspanne: At 1 year

Percentage of participants with at least 66% of platelet counts collected at year 1 (between study days 296 and 379) equal to or above 50 G/L in the absence of rescue treatment/new ITP treatment.

At 1 year
Bleeding events according to the Modified World Health Organization (WHO) bleeding scale
Tijdsspanne: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Number of participants reporting bleeding events for each grade of the World Health Organization (WHO) bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Percentage of participants with bleeding events according to the Modified World Health Organization (WHO) bleeding scale
Tijdsspanne: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Percentage of participants reporting bleeding events for each grade of the WHO bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Number of participants who received rescue treatment
Tijdsspanne: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Number of participants who required rescue treatment

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Percentage of participants who received rescue treatment
Tijdsspanne: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Percentage of participants who required rescue treatment

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from baseline in the frequency of CD19+ B-cell counts
Tijdsspanne: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline frequency of CD19+ B-cell counts compared to baseline

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from baseline in the absolute number of CD19+ B-cell counts
Tijdsspanne: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline absolute number of CD19+ B-cell counts compared to baseline

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Time to first occurrence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL
Tijdsspanne: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from baseline in immunoglobulins
Tijdsspanne: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline immunoglobulin levels (change in titers of Total Ig, IgG, IgM, IgA) compared to baseline

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Incidence of anti-ianalumab antibodies in serum (ADA assay) over time
Tijdsspanne: Up to 20 weeks after last dose of ianalumab

Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab

Up to 20 weeks after last dose of ianalumab
Titer of anti-ianalumab antibodies in serum (ADA assay) over time
Tijdsspanne: Up to 20 weeks after last dose of ianalumab

Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab

Up to 20 weeks after last dose of ianalumab
Ianalumab serum concentrations over time
Tijdsspanne: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

Ianalumab concentration in serum over time, including end of infusion and concentration at trough.

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
Ianalumab serum PK: AUC concentrations over time
Tijdsspanne: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

Ianalumab concentration in serum over time, including end of infusion and concentration at trough.

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
Ianalumab serum PK parameters: Cmax
Tijdsspanne: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

Maximum (peak) observed plasma, blood, serum or other body fluid drug concentration

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
Ianalumab serum PK parameters: Tmax
Tijdsspanne: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

Time to reach maximum (peak) observed plasma, blood, serum or other body fluid drug concentration

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
Confirmed response (CR) in the second course
Tijdsspanne: Second course Week 1 Day1 to second course Week 25 Day1

Confirmed response is defined as a platelet count of equal or above 50 G/L at two (or more) consecutive assessments at least 7 days apart, in the absence of:

  • Rescue treatment for ≥4 weeks prior to the assessment of the platelet count, and
  • New ITP treatment before reaching a confirmed response.
Second course Week 1 Day1 to second course Week 25 Day1
Time to confirmed response in the second course
Tijdsspanne: Second course Week 1 Day 1 to second course Week 25 Day 1

two (or more) platelet assessments meeting the criteria of a confirmed response.

Second course Week 1 Day 1 to second course Week 25 Day 1
Duration of confirmed response in the second course
Tijdsspanne: Second course Week 1 Day 1 to second course Week 25 Day 1

Time from the first assessment, in the second course of two (or more) platelet assessments meeting the criteria of a confirmed response to loss of response; with loss of response defined as the first of the following events:

  • platelet count <30 G/L,
  • start of any rescue or new ITP treatment,
  • death (whatever the cause).
Second course Week 1 Day 1 to second course Week 25 Day 1
Response in the second course
Tijdsspanne: Second course Week 1 Day 1 to second course Week 25 Day 1

Percentage of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment.

Second course Week 1 Day 1 to second course Week 25 Day 1
Complete Response in the second course
Tijdsspanne: Second course Week 1 Day 1 to second course Week 25 Day 1

Percentage of participants with a platelet count of at least 100 G/L in the absence of rescue treatment/new ITP treatment.

Second course Week 1 Day 1 to second course Week 25 Day 1
Bleeding events in the second course according to the Modified World Health Organization (WHO) bleeding scale
Tijdsspanne: Second course Week 1 Day 1 to second course Week 25 Day 1

Number of participants reporting bleeding events for each grade of the World Health Organization (WHO) bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

Second course Week 1 Day 1 to second course Week 25 Day 1
Percentage of participants with bleeding events in the retreatment/second courseaccording to the Modified World Health Organization (WHO) bleeding scale
Tijdsspanne: Second course Week 1 Day 1 to second course Week 25 Day 1

Percentage of participants reporting bleeding events for each grade of the WHO bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

Second course Week 1 Day 1 to second course Week 25 Day 1
Number of Participants who received rescue treatment after second course
Tijdsspanne: Second course Week 1 Day 1 to second course Week 25 Day 1

Number of participants who required rescue treatment

Second course Week 1 Day 1 to second course Week 25 Day 1
Percentage of participants who received rescue treatment after receiving second course
Tijdsspanne: Second course Week 1 Day 1 to second course Week 25 Day 1

Percentage of participants who required rescue treatment

Second course Week 1 Day 1 to second course Week 25 Day 1
Titer of anti-ianalumab antibodies in serum (ADA assay) over time for second course
Tijdsspanne: Second course Week 1 Day 1 until 20 weeks after last dose of ianalumab

Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab

Second course Week 1 Day 1 until 20 weeks after last dose of ianalumab
Change from start of second course in immunoglobulins
Tijdsspanne: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline immunoglobulin levels (change in titers of Total Ig, IgG, IgM, IgA) compared to retreatment baseline

From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from start of second course in the absolute number of CD19+ B-cell counts
Tijdsspanne: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline absolute number of CD19+ B-cell counts compared to baseline

From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from start of second course to end of study in the absolute number of CD19+ B-cell counts
Tijdsspanne: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline absolute number of CD19+ B-cell counts compared to baseline

From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Time to first occurrence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL
Tijdsspanne: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL

From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Ianalumab serum concentrations over time in the second course
Tijdsspanne: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose) in the second course

Ianalumab concentration in serum over time, including end of infusion and concentration at trough.

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose) in the second course

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

16 augustus 2023

Primaire voltooiing (Werkelijk)

5 februari 2025

Studie voltooiing (Geschat)

19 maart 2029

Studieregistratiedata

Eerst ingediend

15 mei 2023

Eerst ingediend dat voldeed aan de QC-criteria

30 mei 2023

Eerst geplaatst (Werkelijk)

2 juni 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

20 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

19 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren